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 Abstract 
MDM2 and MDM4, a structurally related MDM2 homolog, negatively regulates expression 
and functions of TP53 tumor suppressor gene. To explore the precise expression patterns and 
function of MDM2 and MDM4 in wild-type (wt) TP53 cancer cells, we analyzed 11 various 
cancer cell lines with wt TP53. All cell lines exhibited deregulated expression of MDM2 or 
MDM4, and were divided into two distinct types; the one expressing high levels of MDM4 
and another expressing low levels of MDM4. The low MDM4 type expressed higher MDM2 
levels than the high MDM4 type. In cells with high MDM4 expression, knockdown of 
MDM4 or MDM2 reactivated TP53, and simultaneous knockdown of MDM2 and MDM4 
synergistically reactivated TP53. In contrast, in cells with low MDM4 expression, 
knockdown of only MDM2 reactivated TP53. These results suggest that both MDM2 and 
MDM4 are closely involved in TP53 inactivation in cancer cells with high MDM4 expression, 
whereas only MDM2, and not MDM4, is a regulator of TP53 in cells with low MDM4 
expression. MDM4 expression in wt TP53-tumors is a potential indicator for TP53 
reactivation cancer therapy by simultaneous targeting of MDM4 and MDM2. Specific 
knockdown of MDM2 and MDM4 might be applicable for TP53 restoration therapy. 
  
 Introduction 
The tumor suppressor protein p53 is a transcriptional factor that controls multiple genes to 
regulate the cell cycle, apoptosis, DNA repair, and senescence [1-4]. Approximately half of 
human cancers have mutations in the TP53 gene [5], indicating that TP53 inactivation is 
pivotal in cancer development. The remaining cancers retain the wild-type (wt) status of 
TP53, which is inhibited by deregulated upstream modulators and/or inactivation of 
downstream effectors [1, 6]. 
The human homolog of murine double minute 2 (MDM2) is a major negative 
regulator of p53 through binding to its transactivation domain, thereby resulting in 
subsequent suppression of transcriptional activity [7, 8]. In addition, the RING (Really 
Interesting New Gene) finger domain of MDM2 functions as an E3 ubiquitin ligase that 
mediates ubiquitin-dependent degradation of p53 [9-11]. MDM2 is a transcriptional target of 
p53, forming an autoregulatory feedback loop [12, 13]. TP53 is also negatively regulated by 
MDM4, an MDM2 homologue [14, 15]. Like MDM2, MDM4 represses p53 transcriptional 
activity by direct binding of its binding domain, which is located in the N-terminal region, to 
the transactivation domain of p53 [14]. Although MDM4 possess a RING finger domain, it 
lacks E3 ligase activity and is unable to directly decrease p53 stability [14], but rather 
enhances the E3 ligase activity toward p53 by forming a heterodimer with MDM2 via the 
RING domains of both molecules [16, 17]. MDM2 also destabilizes the structure of MDM4 
via ubiquitination [18]. Both MDM2 and MDM4 function as oncogenes and their deregulated 
expression has been reported in various types of human cancers, including soft tissue sarcoma, 
breast cancer, retinoblastoma, and melanoma [19-23]. However, to date, the expression 
patterns and functional roles of MDM2 and MDM4 in cancer cells with or without TP53 
mutations remain uncertain. 
 Restoration of wt TP53 function in tumors leads to rapid tumor regression by 
induction of apoptosis or senescence and can be applicable to cancer treatment [19]. Several 
small molecular inhibitors of the interactions between MDM2 and p53 have been shown to 
restore TP53 activity in tumors expressing high MDM2 levels [24-26]. Similarly, MDM4 
antagonists have been reported. Among them, SAH-p53-8 binds and inhibits more efficiently 
to MDM4 than to MDM2 and exerts antitumor effects in cancer cells expressing high MDM4 
levels [21, 27].  
Synthetic small interfering RNAs (siRNAs) are not only a powerful tool for functional 
gene analysis [28, 29], but has been intensively explored for application to therapy of  human 
cancer and other diseases with some promising results [30-32]. siRNAs often silence the 
expression of untargeted genes with partial sequence complementarities (off-target effects) 
[33, 34]. Base-paring between mRNA sequences and the seed regions of siRNA guide strands 
(nucleotide positions 2–8 from the 5′ end) may be sufficient for off-target silencing [33]. 
However, such nonspecific effects can be avoided by DNA replacement in the seed region of 
the guide strand (first 6–8 bases from the 5′ end) and the complementary sequences of the 
passenger strand, which has been designated as a double-stranded RNA–DNA chimera 
(dsRDC) [35]. Additionally, dsRDCs are more stable in the human serum than the 
conventional siRNA due to resistance to endogenous ribonuclease [36]. Considering the 
recent progress in RNAi technology, synthetic siRNAs targeting MDM2 and MDM4 may 
present an alternative mechanism to induce TP53 restoration.  
In the present study, we carefully analyzed MDM2 and MDM4 expression levels in 
various cancer cell lines with and without TP53 mutations and found that MDM2 or MDM4 
were deregulated in all wt TP53 cancer cells. To probe the roles of MDM2 and MDM4 in 
TP53 regulation in cancer cells, we selected efficient and specific dsRDC-modified siRNAs 
targeting MDM2 and MDM4. Individual and combined knockdown of MDM2 and MDM4 
 revealed their roles in TP53 inactivation in wt TP53 cancer cells with different patterns of 
MDM2 and MDM4 expression, which provided us with a rationale for the selection of 
MDM2 and MDM4 as targets in TP53 restoration therapy of cancers. 
 
Results 
Expression levels of MDM2 and MDM4 in cancer cell lines 
We examined the expression levels of MDM2 and MDM4 in 14 cancer cell lines including 11 
wt TP53 and three mutant (mt) TP53 cell lines by immunoblotting (Figure 1). wt TP53 cell 
lines were divided into two groups according to levels of MDM4: seven cell lines (MCF-7, 
A375, SNU-1, HCT116, NUGC-4, LoVo, and A549) expressed high levels of MDM4, 
whereas the remaining four cell lines (SJSA-1, HepG2, HuH-6, and C32TG) expressed low 
levels of MDM4. Interestingly, all cell lines expressing low MDM4 levels accumulated 
higher levels of MDM2 than those expressing high MDM4 levels. Cell lines carrying mt 
TP53 (KATOIII, NUGC-3, and DLD-1) expressed various levels of MDM4 and MDM2. p53 
was not detected in KATOIII cells, which harbored gross deletions of both TP53 alleles. 
 
Efficient siRNAs targeting MDM2 and their DNA-modified forms 
Seventeen new siRNAs targeting human MDM2 transcript variant 1 (NM_002392.4) were 
selected using siDirect software (Supplementary Table 1) [37]. These siRNAs contained at 
least three mismatched base pairs in both the guide and passenger strands with a non-
redundant sequence set of human genes to minimize off-target effects [38]. siRNA sequences 
containing single-nucleotide polymorphisms were also excluded to avoid individual 
differences in response. These new siRNAs targeting MDM2 (siMDM2) and nine previously 
 reported siMDM2s were synthesized and tested for knockdown efficiency by transfection into 
SJSA-1 cells and subsequent immunoblot analysis (Figure 2a) (Supplementary Figure 1). Six 
new (1068, 830, 480, 691, 1489, and 2381) and two previously reported siMDM2s (396 and 
851) strongly suppressed MDM2 expression. These siMDM2s were converted to dsRDCs 
with the aim to further reduce off-target effects by decreasing the free energy of pairing 
stability between the seed region and off-target mRNAs [35]. As shown in Figure 2b, all 
dsRDC-modified siMDM2s (chiMDM2) were able to silence MDM2 expression with the 
most efficient silencing achieved by chiMDM2-1489. Quantitative reverse transcription 
(qRT)-PCR analysis demonstrated the ability of these chiMDM2s to knockdown mRNA to 
the same or a slightly reduced extent as compared with cognate siRNAs (Supplementary 
Figure 2). 
The effect of chiMDM2s on the growth of cancer cells with high MDM2 expression 
was examined. SJSA-1 cells were transfected with chiMDM2s at 1 nM for 5 days and then 
subjected to the WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium) cell proliferation assay. As shown in Figure 2c, most of the 
chiMDM2s suppressed the growth of SJSA-1 cells in proportion to the individual MDM2 
knockdown efficiency, with the exception of chiMDM2-1068, which suppressed cell growth 
to a greater extent than chiMDM2-1489, although the MDM2 knockdown efficiency was 
inversed, suggesting that chiMDM2-1068 partially exerted MDM2–p53-indepndent growth 
suppression. Therefore, these two chiMDM2s were further analyzed for growth suppression 
of cancer cells carrying mt TP53 (KATO III, NUGC-3, and DLD-1) (Figure 2d). chiMDM2-
1489 and chiMDM2-1068 exhibited negligible effects on these cells, with the exception of 
chiMDM2-1068-mediated suppression of NUGC-3 cell growth. 
 
 Selection of siRNAs targeting MDM4 and their DNA-modified forms 
siRNAs targeting the coding region of human MDM4 transcript variant 1 (NM_002393.4) 
were similarly selected as those targeting MDM2. Ten new MDM4 siRNAs (siMDM4) 
(Supplementary Table 1) were examined for MDM4 knockdown efficiency in MCF-7 cells, 
which exhibit high levels of MDM4 expression, by immunoblot analysis (Figure 3a). Seven 
siMDM4s (317, 347, 452, 582, 788, 861, and 1036) showed strong suppression of MDM4 
expression and were converted to dsRDCs (chiMDM4). Six chiMDM4s (317, 347, 452, 788, 
861, and 1036) knocked down MDM4 expression in MCF-7 cells as efficiently as their 
cognate siRNAs (Figure 3b). Among these six chiMDM4s, chiMDM4-452 exhibited the 
highest silencing activity. qRT-PCR analysis confirmed efficient MDM4 knockdown by each 
of these chiMDM4s (Supplementary Figure 3). The effect on viability of MCF-7 cells by 
these chiMDM4s was also tested using the WST-8 assay (Figure 3c). All chiMDM4s induced 
growth suppression in parallel to the MDM4 knockdown efficiency of each. In fact, potent 
growth suppression was observed with most chiMDM4s (317, 347, 452, 788, 861, and 1036). 
chiMDM4-582 exhibited less efficient MDM4 silencing and growth inhibitory activities of 
MCF-7 cells than other chiMDM4s.  
Next, the effect of each chiMDM4 on the growth of mt TP53 cancer cells was 
evaluated. Six effective chiMDM4s were introduced into three mt TP53 cancer cell lines 
(KATO III, NUGC-3, and DLD-1) and examined for effects on cell growth suppression using 
the WST-8 assay. As shown in Figure 3d, chiMDM4-452 and -1036 showed negligible 
growth suppression, whereas other chiMDM4s exhibited mild growth suppression, but 
without any statistical differences. 
 
Effects of MDM4 and MDM2 knockdown on growth of wt TP53 cancer cells 
 To examine the effect of MDM4 and MDM2 knockdown on the growth of wt TP53 cancer 
cells, we tested the 11 previously mentioned wt TP53 cancer cell lines, which included seven 
with high levels of MDM4 expression (MCF-7, A375, SNU-1, HCT116, NUGC-4, LoVo, and 
A549) and four with low levels of MDM4 expression (SJSA-1, HepG2, HuH-6, and C32TG). 
To knock down MDM2 and MDM4, two dsRDCs were chosen for each target (chiMDM2-
1068/-1489 and chiMDM4-452/-1036). As shown in Figure 4, each chiMDM2 inhibited 
growth of all wt TP53 cancer cells regardless of the expression levels of MDM2 or MDM4, 
whereas chiMDM4 only suppressed the growth of cells with high MDM4 expression and not 
of those with low MDM4 expression (Figure 4). 
Next, we examined the effects of MDM2 and MDM4 knockdown on expression levels 
of p53 and p21Waf1/Cip1 (p21), a TP53 responsive gene product [39], by immunoblotting. As 
shown in Figure 5, MDM2 suppression increased levels of p53 and p21 in all wt TP53 cells. 
MDM4 slightly accumulated in most of the wt TP53 cells after MDM2 knockdown, with the 
exception of SJSA-1 and HepG2 cells. As shown in Figure 6, in all cells with high MDM4 
expression, MDM4 knockdown slightly increased p53 levels in association with the induction 
of p21 and MDM2, which are known TP53-responsive genes, but had negligible effects on 
p53, p21, and MDM2 in cells with low MDM4 expression.  
 The effects of MDM2 and MDM4 knockdown on p53 and MDM4 varied among three 
mt TP53 cell lines. As shown in Figures 5, MDM2 knockdown induced mild MDM4 
accumulation in NUGC-3 and DLD-1 cells, but not KATOIII cells. As shown in Figure 6, 
MDM4 knockdown reduced MDM2 levels in all three mt TP53 cell lines. Accumulation of 
p53 occurred in DLD-1 cells, which expressed low levels of mt p53, but not in NUGC-3 cells, 
which expressed high levels of mt p53. The induction of p21 did not occur in any of these mt 
TP53 cell lines in response to MDM2 or MDM4 knockdown. 
  
Effects of MDM2/MDM4 double knockdown on growth of wt TP53 cancer cells 
We examined the effect of MDM2/MDM4 double knockdown on growth of wt TP53 cells, 
which had high MDM4 expression, using chiMDM4-452 and chiMDM2-1489, which were 
the most potent and specific inhibitors of each respective target. Cells were transfected with 
various chiMDM4 concentrations along with control dsRDC-modified siRNA (chiCtrl) at a 
total dosage of 2 nM, as indicated. As shown in Figure 7a, chiMDM4 and chiMDM2 
suppressed the growth of MCF-7 and A375 cells in a dose-dependent manner. When 
chiMDM2 and chiMDM4 were simultaneously transfected at three different ratios, more 
profound growth suppression was observed in these cells than transfection of either 
chiMDM2 or chiMDM4 alone at the same dosage, or even at a maximal dosage of 2 nM. 
Similar enhancement in growth suppression was observed in all cells with high MDM4 
expression, including five other cell lines (SNU-1, HCT116, NUGC-4, LoVo, and A549) 
(Supplementary Figure 4). Combination index values at three different ratios of chiMDM2 
and chiMDM4 were calculated in cells with high MDM4 expression with values ranging 
between 0.20 and 0.72, which showed that these dsRDCs promoted synergistic growth 
inhibition of tumor cells with high MDM4 expression (Table 1).  
chiMDM2, but not chiMDM4, alone dose-dependently suppressed the growth of cells 
with low MDM4 expression (SJSA-1 and C32TG). Further, chiMDM2-mediated growth 
inhibition was not enhanced by co-transfection with chiMDM4 in these cells (Figure 7a). 
Similar results were observed in two other cell lines with low MDM4 expression 
(Supplementary Figure 5). In mt TP53 cells, chiMDM2, chiMDM4, and a combination of 
both failed to demonstrate any detectable growth suppression (Supplementary Figure 5). 
 
 Effect of MDM2/MDM4 double knockdown on p53 expression 
To explore the mechanism by which MDM2/MDM4 double knockdown 
synergistically inhibited the growth of cells with high MDM4 expression, the effects of 
individual and simultaneous knockdown of MDM2 and MDM4 on p53 expression was 
examined in MCF-7 and A375 cells (Figure 7b). MDM2 knockdown was associated with 
mild accumulation of MDM4 and p53, as well as the product of the downstream gene p21. 
MDM4 knockdown slightly increased levels of MDM2 and p21 in these cells. A subtle 
increase in p53 expression was observed in chiMDM4-transfected A375 cells, but not in 
chiMDM4-transfected MCF-7 cells. Simultaneous knockdown by chiMDM2 (1 nM) and 
chiMDM4 (1 nM) induced expression of p53 and the downstream p21 gene product more 
than either chiMDM2 or chiMDM4 alone at 1 or 2 nM in cell lines with high MDM4 
expression (MCF-7, A375). In cells with low MDM4 expression (SJSA-1 and C32TG), 
chiMDM2 alone knocked down MDM2, which resulted in accumulation of both p53 and p21 
(Figure 7b). However, chiMDM4 did not induce either p53 or p21 upregulation even though 
MDM4 was efficiently suppressed. Co-transfection of chiMDM2 and chiMDM4 induced 
accumulation of p53 and p21 to the same extent as chiMDM2. 
 
Discussion 
A fraction of wt TP53 tumors expresses oncogenes, such as MDM2 and MDM4, to inactivate 
TP53 [19]. Precise expression patterns and the functional significance of MDM2 and MDM4 
in wt TP53 cancer cells remain to be clarified. In the present study, a careful analysis of 
cancer cell lines harboring wt and mt TP53 demonstrated that all wt TP53 cancer cell lines 
included in this study exhibited deregulated expression of MDM2 or MDM4. These cell lines 
were divided into just two distinct types, according to MDM4 expression levels; the one 
 expressing MDM4 at high levels and another expressing MDM4 at low levels. MDM4 
expression occurs when tumor cells have acquired MDM4 amplification [19], activated KRAS 
mutations [40], or loss of miR-34a-mediated suppression [41]. Among seven wt TP53 cancer 
cell lines with high MDM4 expression, one cell line (MCF-7) has MDM4 amplification [42]. 
Four cell lines (SNU-1, HCT116, LoVo, A549) harbor KRAS mutation [43, 44], suggesting 
that the deregulated expression of MDM4 may be caused by KRAS activation or along with 
miR-34a abnormality in these cell lines. 
It is well established that MDM2 and MDM4 are ideal therapeutic targets for wt TP53 
tumors. However, to date, there is no biological rationale of whether MDM2 or MDM4 should 
be targeted in such tumors. Using wt TP53 cell lines and DNA-modified siRNAs specific to 
MDM2 and MDM4, we demonstrated here for the first time that knockdown of either MDM4 
or MDM2 alone can reactivate the TP53 pathway in cancer cells with high MDM4 expression, 
whereas knockdown of MDM2, but not MDM4, can reactivate wt TP53 in the low MDM4 
cancer cells. Furthermore, simultaneous knockdown of MDM2 and MDM4 synergistically 
activated TP53 and suppressed cell growth in the cancer cells with high MDM4 expression. 
Based on these results, we propose that both MDM4 and MDM2 are efficient therapeutic 
targets in wt TP53 tumors cells with high MDM4 expression, whereas MDM2, but not 
necessarily MDM4, presents a possible therapeutic target in wt TP53 cancer cells with low 
MDM4 expression. 
We explored the mechanisms by which MDM2/MDM4 double knockdown exhibited 
synergistic effects on TP53 activation in tumor cells with high MDM4 expression. MDM4 is 
devoid of a nuclear transport signal and requires MDM2 to translocate from the cytoplasm to 
nucleus [45, 46]. Therefore, we assessed whether the synergistic effect of MDM2/MDM4 
double knockdown on TP53 activation was mediated through the inhibition of nuclear 
transport of MDM4 by MDM2 (Supplementary Figure 6). We found that MDM2 knockdown 
 had no effect on nuclear localization of MDM4 in cells with high MDM4 expression (A375), 
suggesting that this nuclear localization was independent of MDM2 expression in these cells 
and that synergistic activation of TP53 was not mediated by inhibition of nuclear transport of 
MDM4 in these cells. In cells with high MDM4 expression, MDM4 silencing alone increased 
p53 expression. Because MDM4 has no intrinsic ubiquitin ligase function, but can enhance 
MDM2 ubiquitin ligase activity by forming a heterodimer with MDM2 [14, 17], both MDM2 
and MDM4 may be involved in p53 degradation through the formation of heterodimers. 
Alternatively, MDM4 knockdown alone enhances MDM2 expression by releasing p53 
transcriptional activity, which subsequently suppresses p53 [12, 14, 47]. Therefore, 
simultaneous knockdown of MDM4 and MDM2 may result in more potent activation of p53 
by blocking this p53-MDM2 negative feedback than silencing MDM4 alone. 
With the aim to employ synthetic siRNAs in TP53-restoration therapy, we carefully 
designed and screened siRNAs with high specificities and potencies to target either MDM2 or 
MDM4. A series of siRNAs targeting MDM2 and MDM4 was designed using siDirect 
software, which enabled the selection of siRNA sequences with structural features compatible 
for the efficient loading of the guide strand into the RNA-induced silencing complex as well 
as a minimal number of off-target candidates from human genes [37, 48]. Among them, 
effective siRNAs with high knockdown efficiency were chosen by cell-transfection 
experiments and then converted to DNA-modified siRNAs with 6-base pair double-stranded 
DNA substitutions [35]. This modification offers a great advantage by lowering off-target 
activity by decreasing the free energy between the seed regions and off-target mRNAs and 
avoiding passenger strand-mediated RNAi [35, 49]. Three dsRDCs targeting MDM2 
(chiMDM2-1489, 1068, and 2381) and six targeting MDM4 (chiMDM4-861, 452, 1036, 317, 
347, and 788) showed potent silencing activity at a concentration as low as 1 nM. siRNAs 
interfere with the endogenous miRNA pathway by competing with molecules involved in 
 miRNA production, such as AGO2, when introduced at high concentrations [50-52]. 
Intracellular concentrations of most functional miRNAs are between 3 and 100 nM [53]. To 
avoid disruptions to the miRNA pathway, it is necessary to introduce siRNAs with high 
silencing activities into cells at the lowest concentrations possible. dsRDCs targeting MDM2 
and MDM4 selected in this study had a half maximal inhibitory concentration (IC50 value) of 
less than 1 nM and were used at 1 nM in most of our experiments. With the development of 
an efficient delivery system of oligonucleotides, dsRDCs targeting MDM2 and MDM4 could 
be applied to the treatment of wt TP53 cancers. 
Some earlier reports using TP53 switchable mice with MDM2- and MDM4-deficient 
backgrounds showed transient restoration of TP53 activity in normal tissues in the absence of 
MDM2, resulting in 100% fatality within 5–6 days [54], whereas TP53 activation in the 
absence of MDM4 was nonlethal and reversible [55]. These data indicate that systemic 
administration of MDM4 inhibitors may be better tolerated than MDM2 inhibitors, therefore, 
MDM4 knockdown using our dsRDC might be a valuable therapeutic strategy for treatment 
of tumors with high MDM4 expression levels but no TP53 mutations. Currently, we are 
exploring expression patterns of MDM2, MDM4, and p53 as well as the genotypes of various 
human tumor samples. 
Some cancer cells expressing high levels of MDM4 are reportedly resistant to small-
molecule MDM2 inhibitors [56-58]. However, our results clearly demonstrated that specific 
MDM2 knockdown suppressed growth of wt TP53 cells regardless of the expression levels of 
MDM2 and MDM4. The action mechanisms of small molecular inhibitors and siRNAs differ 
because small molecular inhibitors bind MDM2 at the p53-binding pocket and disrupt 
MDM2–p53 interactions and increase p53 expression, resulting in enhanced MDM2 induction, 
which might dysregulate other MDM2-target molecules. In contrast, siRNAs targeting MDM2 
suppress only MDM2. This phenomenon might explain the discrepancy in our results. 
 Besides controlling TP53 activity, MDM2 has been reported to regulate E2F1 
transcriptional activity and expression of p21, FOXO3a, and XIAP [59-62]. MDM4 has been 
also reported to inhibit p21 and Smad family proteins [63, 64]. The results of the present 
study showed that knockdown of MDM2 and MDM4 by respective dsRDCs at 1 nM had no 
effect on growth of mt TP53 cancer cells expressing various levels of MDM4, suggesting that 
growth suppression by MDM2 and MDM4 knockdown is entirely dependent on wt TP53 and 
that suppression of TP53-independent activities had a minimal effect on vitro growth of 
tumors expressing mt TP53. The mild growth suppression of NUGC-3 and DLD-1 cells 
observed by transfection of chiMDM2-1489 at 2 nM suggested the presence of nonspecific 
effects, such as inhibition of miRNA generation, even though the siRNA concentration was 
very low. 
In conclusion, we showed that most wt TP53 cancer cells exhibited deregulation of 
MDM2 and MDM4. Specific knockdown of MDM2 and MDM4 with DNA-modified siRNAs 
clearly revealed the ability of MDM2 and MDM4 to inactivate wt TP53 in cancer cells. The 
results of this study provide rationale for the selection of MDM2 and MDM4 as therapeutic 
targets in cancer cells expressing wt TP53. MDM4 expression in wt TP53-tumors is a 
potential indicator for TP53 reactivation by combined MDM4 and MDM2-targeted cancer 
therapy. Our specific and potent DNA-modified siRNAs targeting MDM2 and MDM4 might 
be applicable to TP53 restoration therapy for human cancers. 
 
Materials and methods 
Cell lines 
Fourteen tumor cell lines were used: eleven cell lines with wt TP53 (MCF-7 breast cancer, 
A375 melanoma, HCT116 colon cancer, NUGC-4 gastric cancer, LoVo colon cancer, SJSA-1 
 osteosarcoma, HepG2 hepatocellular carcinoma, HuH-6 hepatocellular carcinoma, A549 lung 
cancer, and C32TG melanoma) [43, 65-67], and three cell lines with mt TP53 (KATOIII 
gastric cancer, NUGC-3 gastric cancer, and DLD-1 colon cancer) [65]. The MCF-7, A375, 
SNU-1, HCT116, LoVo, SJSA-1, and DLD-1 cell lines were purchased from the American 
Type Culture Collection (Rockville, MD, USA). The NUGC-4, HepG2, and KATOIII cell 
lines were obtained from the Riken BioResource Center Cell Bank (Tsukuba, Japan). The 
NUGC-3, A549, HuH-6 and C32TG cell lines were obtained from the Japanese Collection of 
Research Bioresources Cell Bank (Osaka, Japan). MCF-7, SNU-1, NUGC-4, SJSA-1, 
KATOIII, NUGC-3, and DLD-1 cells were cultured in RPMI 1640 medium (Sigma–Aldrich, 
St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Nichirei Biosciences, 
Tokyo, Japan). A375, HepG2, and HuH-6 cells were cultured in Dulbecco’s modified Eagle’s 
medium (Sigma–Aldrich) containing 10% FBS. HCT116 cells were cultured in McCoy’s 5A 
medium (Sigma–Aldrich) with 10% FBS. LoVo cells were cultured in Ham’s F12K medium 
(Invitrogen, Carlsbad, CA, USA) with 10% FBS. 
 
 siRNAs and transfection 
Sequences of siRNAs used in this study are summarized in Supplementary Table 1. All 
siRNAs targeting MDM2 and MDM4 were designed using siDirect software 
(http://sidirect2.rnai.jp), as reported previously [37]. The control siRNA was an artificial 
sequence designed to have all features of siRNAs inducing potent RNAi and the least 
homology to human and mouse genes. Control-R siRNA consisted of randomized sequences 
of the control siRNA. Control siRNA and complementary dsRDC-modified forms were 
included in all experiments. siRNAs were converted to dsRDCs by substituting six 
ribonucleotides from the 5′ end of the guide strand and eight from the 3′ end of the passenger 
 strand with corresponding deoxynucleotides [35, 68]. siRNA transfection was performed 
using Lipofectamine RNAiMAX (Invitrogen) as reported previously [68]. 
 
Immunoblot analysis 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot analysis were 
performed as previously described [69]. The primary and secondary antibodies used in this 
study were as follows: mouse monoclonal antibody against MDM2 (2A10) (Abcam, 
Cambridge, UK); rabbit polyclonal antibody against MDM4 (Bethyl Laboratories, 
Montogomery, TX, USA); mouse monoclonal antibodies against p21Waf1/Cip1 (DCS60) and -
actin (8H10D10) (Cell Signaling Technology, Danvers, MA, USA); and anti-TP53 mouse 
monoclonal antibody (BP53-12; Cell Sciences, Canton, MA, USA). Both horseradish 
peroxidase-conjugated anti-mouse IgG sheep and anti-rabbit IgG donkey sera were purchased 
from GE Healthcare (Buckinghamshire, UK). Chemiluminescent detection was performed 
using ECL Prime Western Blotting Detection Reagent (GE Healthare) and the Ez-Capture II 
Imaging System (Atto Corp., Tokyo, Japan). 
Quantitative reverse transcription (qRT)-PCR 
RNA samples were extracted from cell lysate using 40 µL per well of RealTime ready Cell 
Lysis reagent (Roche Diagnostics, Mannheim, Germany), according to the manufacturer’s 
instructions. cDNA was synthesized using 2 µL of RNA and Transcriptor Universal cDNA 
Master (Roche Diagnostics) in 20 µL-reactions. qRT-PCR assays were performed using 
Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, 
USA) in 96-well plates. Primers and TaqMan probes for MDM2, MDM4, and 18S ribosomal 
RNA (18SrRNA) were obtained from Applied Biosystems (Assay ID: Hs00234753, 
Hs00967238, and Hs03928990_g1, respectively). Reactions were performed in duplicate 
 under standard thermocycling conditions in a 20-µL volume containing 0.8 µL of cDNA, 900 
nM of primers, 250 nM of the probe, and 10 µL of TaqMan Gene Expression Master Mix 
(Applied Biosystems), according to the manufacturer’s protocol. The amount of target mRNA 
was examined and normalized to that of 18S rRNA. 
 
Cell viability 
WST-8 colorimetric assays were performed using a Cell Counting kit-8 (Dojin Laboratories, 
Kumamoto, Japan) according to the manufacturer’s protocol. Cells were incubated for 5 days 
after transfection and then analyzed using an iMark microplate reader (Bio-Rad, Hercules, 
CA, USA). The absorbance of the plates was read at wavelengths of 450 nm and 620 nm. 
 
Combination index. 
Quantification of chiMDM2 and chiMDM4 synergy was determined by the Chou–Talalay 
method for drug combination using CalcuSyn software (Biosoft, Cambridge, UK) [70]. A 
combination index (CI) < 0.9 indicates synergism, 09–1.1 indicates additivity, and >1.1 
indicates antagonism. 
 
Immunofluorescence 
Cells were fixed for 15 min in 4% paraformaldehyde at room temperature, and aldehydes 
were neutralized by soaking coverslips in phosphate-buffered saline (PBS) with 0.1% tween 
20 (PBS-T) containing 50 mM glycine at room temperature. Then, the cells were 
permeabilized in PBS-T with 0.1% Triton X-100 solution for 15 min on ice, blocked for 60 
min in PBS-T solution containing 5% normal goat serum (Vector Laboratories, Burlingame, 
 CA, USA) (blocking solution) at room temperature, and then reacted with rabbit polyclonal 
antibody against MDM4 (Bethyl Laboratories) diluted with blocking solution. After 
overnight incubation at 4°C, the cells were reacted with fluorescein isothiocyanate-
conjugated goat anti-rabbit IgG antibody (Bethyl Laboratories) diluted with washing buffer 
for 60 min at room temperature. Nuclei were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI). Confocal fluorescence images were obtained using Leica TCS SP5 
confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany) 
 
Statistical analysis. 
All data are expressed as the mean ± standard deviation (SD). Statistical signiﬁcance of 
differences between various groups was evaluated using the Dunnett’s test. P-values < 0.05 
were considered significant. 
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Figure Legends 
Figure 1. Expression levels of p53, MDM2, and MDM4 in cancer cell lines. 
Expression levels of p53, MDM2, and MDM4 were examined in 14 cancer cell lines (11 wt 
TP53 cell lines and 3 mt TP53 cell lines) by immunoblotting. SE, short exposure; LE, long 
exposure. 
 
Figure 2. Effects of siRNAs targeting MDM2 and their dsRDC forms on MDM2 expression 
and cell growth. (a) Two previously reported (396 and 851) and 17 new siMDM2s were 
analyzed for their effects on MDM2 expression in SJSA-1 cells by immunoblotting. SJSA-1 
cells were transfected with mock, control siRNA (siCtrl), control-R siRNA (siCtrl-R), and 
siMDM2s at 1 nM for 48 h and then examined for MDM2 expression by immunoblotting. (b) 
Control siRNA, control-R siRNA, and eight effective siMDM2s, including two previously 
reported and six new were converted to dsRDC forms (chiCtrl, chiCtrl-R, and chiMDM2s), 
and examined for MDM2 knockdown activity in SJSA-1 cells 48 h after transfection at 1 nM. 
(c) Effect of chiMDM2s on growth of SJSA-1 cells were examined. The cells were 
transfected with control dsRDC (chiCtrl) or eight chiMDM2s at 1 nM for 5 days and then 
assayed for relative viable cell number using the WST-8 assay (mean ± SD; n = 3). (d) The 
 effects of two highly effective chiMDM2s (1068 and 1489) on growth of mt TP53-cancer 
cells (KATOIII, NUCG-3, and DLD-1) after transfection at 1 nM for 5 days were examined 
using theWST-8 assay. Viable cell numbers relative to those transfected with control dsRDC 
(chiCtrl) are shown (mean ± SD; n = 3; *p < 0.05; Dunnett’s test). 
 
Figure 3. Effects of siRNAs targeting MDM4 and their dsRDC forms on MDM4 expression 
and cell growth. (a) The effects of siMDM4s on MDM4 expression were analyzed in MCF-7 
cells by immunoblotting 48 h after transfection with mock, control siRNA (siCtrl), or 10 
siMDM4s at 1 nM. SE, short exposure; LE, long exposure. (b) Seven effective siMDM4s and 
a control siRNA were converted to dsRDC forms (chiMDM4s and chiCtrl), and analyzed for 
MDM4 knockdown in MCF-7 cells 48 h after transfection at 1 nM. (c) The effect of 
chiMDM4s on the growth of MCF-7 cells was examined. The cells were transfected with 
control dsRDC (chiCtrl) or seven chiMDM4s at 1 nM for 5 days and then assayed for relative 
viable cell number using the WST-8 assay (mean ± SD; n = 3). (d) The effects of six highly 
effective chiMDM4s on the growth of mt TP53-cancer cells (KATOIII, NUCG-3, and DLD-
1) after transfecting at 1 nM for 5 days were examined using the WST-8 assay. Viable cell 
numbers relative to those transfected with control dsRDC (chiCtrl) are shown (mean ± SD.; n 
= 3; *p < 0.05; Dunnett’s test). 
 
Figure 4. Effect of MDM2 and MDM4 knockdown on the growth of wt TP53 cell lines. 
dsRDCs targeting MDM2 (chiMDM2-1068 and chiMDM2-1489) (a), MDM4 (chiMDM4-
452 and chiMDM4-1036) (b) and control dsRDC (chiCtrl) were transfected into seven cell 
lines with high MDM4 expression levels (MCF-7, A375, SNU-1, HCT116, NUCG-4, LoVo, 
and A549) and four cell lines with low MDM4 expression levels (SJSA-1, HepG2, HuH-6, 
 and C32TG) at 1 nM. Five days after transfection, cell viability was determined using the 
WST-8 assay. Viable cell numbers relative to those transfected with chiCtrl are shown (mean 
± SD; n = 3; *p < 0.05; Dunnett’s test). 
 
Figure 5. Effect of MDM2 knockdown on expression levels of MDM2, MDM4, p53 and p21. 
Mock, control dsRDC (Ctrl), and two dsRDCs targeting MDM2 (chiMDM2-1068, 
chiMDM2-1489) were transfected into seven cells lines with high MDM4 expression, four 
cell lines with low MDM4 expression and three mt TP53 cell lines at 1 nM. Expression levels 
of MDM2, MDM4, p53, and p21 were analyzed by immunoblotting 2 days after transfection. 
 
Figure 6. Effect of MDM4 knockdown on expression levels of MDM4, MDM2, p53, and p21. 
Mock, control dsRDC (Ctrl), and two dsRDCs targeting MDM4 (chiMDM4-452 and -1036) 
were transfected into seven cell lines with high MDM4 expression, four cell lines with low 
MDM4 expression and three mt TP53 cell lines at 1 nM. Expression levels of MDM2, 
MDM4, p53, and p21 were analyzed by immunoblotting 2 days after transfection. 
 
Figure 7. Combined knockdown of MDM2 and MDM4 in wt TP53 cell lines with high and 
low MDM4 expression. Effects of individual and simultaneous knockdown of MDM2 and 
MDM4 on cell growth (a) and expression of p53 and p21 (b) were examined in two cell lines 
with high MDM4 expression (MCF-7 and A375) and two cell lines with low MDM4 
expression (SJSA-1 and C32TG). Cells were transfected with MDM4 dsRDC (chiMDM4-
452) alone, MDM2 dsRDC (chiMDM2-1489) alone, or both. The total amount of dsRDCs 
was adjusted to 2 nM by adding control dsRDC (chiCtrl). Cell viability was determined 5 
days after transfection using the WST-8 assay. Viable cell numbers of chiCtrl (2 nM) 
 transfected cells was defined as 100% (mean ± SD; n = 3). Levels of MDM2, MDM4, p53, 
and p21 were analyzed by immunoblotting 2 days after transfection. In panel b, + and ++ 
indicates 1 nM and 2 nM of dsRDCs, respectively. 
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Table 1.  Combination index of chiMDM2 and chiMDM4 in MDM4 overexpressed cancer 
cell lines 
chiMDM2 
(nM) 
chiMDM4 
(nM) 
Combination index 
MCF-7 A375 SNU-1 HCT116 NUGC-4 LoVo A549 
0.4 1.6 0.57 0.20 0.36 0.17 0.26 0.55 0.55 
1.0 1.0 0.51 0.28 0.39 0.43 0.39 0.45 0.65 
1.6 0.4 0.47 0.20 0.56 0.44 0.63 0.31 0.72 
CI>1.1, antagonistic effect; CI = 0.9–1.1, additive; CI<0.9, synergistic effects and the lower 
value means the stronger synergistic effect. 
 
SUPPLEMENTAL MATERIALS 
 
 
 
 
 
Supplementary Figure 1: Knockdown efficiency of siRNAs targeting MDM2. SJSA-1 
cells were transfected with mock, control siRNA (siCtrl), and nine reported siMDM2s at 1 
nM for 48 h and then examined for MDM2 expression by immunoblotting. 
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Supplementary Figure 2: Knockdown efficiency of siRNAs targeting MDM2 and their 
dsRDC forms. SJSA-1 cells were transfected with mock, control (Ctrl) siRNA, seven 
siMDM2s, and their dsRDC forms at 1 nM for 48 h and then examined for MDM2 mRNA 
expression by qRT-PCR. All experiments were performed in duplicate. 
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 Supplementary Figure 3: Knockdown efficiency of dsRDC-modified siRNAs targeting 
MDM4. MCF-7 cells were transfected with mock, control dsRDC (chiCtrl), and seven 
dsRDCs targeting MDM4 (chiMDM4) at 1 nM for 48 h and then examined for MDM4 
mRNA expression by qRT-PCR. All experiments were performed in duplicate. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4: Evaluation of combined knockdown of MDM2 and MDM4 on 
the growth of wt TP53 cell lines with high MDM4 expression. Effects of individual and 
simultaneous knockdown of MDM2 and MDM4 on growth were examined in five wt TP53 
cell lines with high MDM4 expression. Cells were transfected with MDM4 dsRDC 
(chiMDM4-452) alone, MDM2 dsRDC (chiMDM2-1489) alone, or both. The total amount of 
dsRDC was adjusted to 2 nM by adding control dsRDC (chiCtrl). Cell viability was 
chiMDM2 - 0.4 1 1.6 2 - - - - 0.4 1 1.6 
chiMDM4 - - - - - 0.4 1 1.6 2 1.6 1 0.4 
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determined 5 days after transfection using the WST-8 assay. The number of viable chiCtrl (2 
nM) transfected cells was defined as 100% (mean ± SD; n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5: Evaluation of combined knockdown of MDM2 and MDM4 on 
the growth of wt TP53 cells with low MDM4 expression and mt TP53 cells. Effects of 
individual and simultaneous knockdown of MDM2 and MDM4 on the cell growth were 
examined in wt TP53 cells with low MDM4 expression (HepG2 and HuH-6) and mt TP53 
cells (KATOIII, NUGC-3, and DLD-1). Cells were transfected with MDM4 dsRDC 
(chiMDM4-452) alone, MDM2 dsRDC (chiMDM2-1489) alone, or both. The total amount of 
dsRDCs was adjusted to 2 nM by adding control dsRDC (chiCtrl). Cell viability was 
chiMDM2 - 0.4 1 1.6 2 - - - - 0.4 1 1.6 
chiMDM4 - - - - - 0.4 1 1.6 2 1.6 1 0.4 
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determined 5 days after transfection using the WST-8 assay. The number of viable chiCtrl (2 
nM) transfected cells was defined as 100% (mean ± SD; n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Supplementary Figure 6: Subcellular localization of MDM4 after MDM2 knockdown. 
A375 cells were transfected with control dsRDC (chiCtrl), MDM2 dsRDC (chiMDM2), or 
MDM4 dsRDC (chiMDM4) at 1 nM for 24 h. Then, the localization of MDM4 was examined 
by immunofluorescence. Cellular nuclei were identified by DAPI staining. 
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Supplementary Table 1: Sequence of siRNAs 
siRNAs  
Nucleotide 
position 
Passenger strand (5'→3') Guide strand (5'→3') References 
siMDM2-347 347-369 CCACCUCACAGAUUCCAGCUU GCUGGAAUCUGUGAGGUGGUU Linares LK et al. 
siMDM2-364 364-386 GCUUCGGAACAAGAGACCCUG GGGUCUCUUGUUCCGAAGCUG Yin JQ et al. 
siMDM2-373 373-395 CAAGAGACCCUGGUUAGACCA GUCUAACCAGGGUCUCUUGUU Linares LK et al. 
siMDM2-396 396-418 GCCAUUGCUUUUGAAGUUAUU UAACUUCAAAAGCAAUGGCUU Jin Y et al. 
siMDM2-636 636-658 UCAGCAGGAAUCAUCGGACUC GUCCGAUGAUUCCUGCUGAUU Carrol VA et al. 
siMDM2-678 678-700 CAGGUGUCACCUUGAAGGUGG ACCUUCAAGGUGACACCUGUU Toh WH et al. 
siMDM2-851 851-873 GCCACAAAUCUGAUAGUAUUU AUACUAUCAGAUUUGUGGCGU Warburton HE et al. 
siMDM2-1644 1644-1666 UGGUUGCAUUGUCCAUGGCAA GCCAUGGACAAUGCAACCAUU Kurki S et al. 
siMDM2-1713 1713-1735 AAGGAAUAAGCCCUGCCCAGU UGGGCAGGGCUUAUUCCUUUU Uchida C et al. 
siMDM2-480 480-502 GUAUAUUAUGACUAAACGAUU UCGUUUAGUCAUAAUAUACUG 
 
siMDM2-643 643-665 GAAUCAUCGGACUCAGGUACA UACCUGAGUCCGAUGAUUCCU 
 
siMDM2-691 691-713 GAAGGUGGGAGUGAUCAAAAG UUUGAUCACUCCCACCUUCAA 
 
siMDM2-830 830-852 CUGGUGAACGACAAAGAAAAC UUUCUUUGUCGUUCACCAGAU 
 
siMDM2-1068 1068-1090 CUCAGAAGAUUAUAGCCUUAG AAGGCUAUAAUCUUCUGAGUC 
 
siMDM2-1274 1274-1296 CCCUUCGUGAGAAUUGGCUUC AGCCAAUUCUCACGAAGGGCC 
 
siMDM2-1275 1275-1297 CCUUCGUGAGAAUUGGCUUCC AAGCCAAUUCUCACGAAGGGC 
 
siMDM2-1489 1489-1511 CAGCCAUCAACUUCUAGUAGC UACUAGAAGUUGAUGGCUGAG 
 
siMDM2-1625 1625-1647 GUCAAGGUCGACCUAAAAAUG UUUUUAGGUCGACCUUGACAA 
 
siMDM2-2370 2370-2392 GGCCUAAAUGUCACUUAGUAC ACUAAGUGACAUUUAGGCCGG 
 
siMDM2-2381 2381-3003 CACUUAGUACCUUUGAUAUAA AUAUCAAAGGUACUAAGUGAC 
 
siMDM2-3412 3412-3434 CCACCAUUUACCCGUAAGACA UCUUACGGGUAAAUGGUGGCU 
 
siMDM2-5187 5187-5209 CUCCAAAGGUAAAAGUACUAA AGUACUUUUACCUUUGGAGGU 
 
siMDM2-6068 6068-6090 GGUUCUUUAUAGUACACGUGU ACGUGUACUAUAAAGAACCUA 
 
siMDM2-6281 6281-6303 GCAGUUGGGAGCCUCCAAUGA AUUGGAGGCUCCCAACUGCUU 
 
siMDM2-6393 6393-6415 GUGAUCGUGAAUGGUCUAUAA AUAGACCAUUCACGAUCACUU 
 
siMDM2-7414 7414-7436 GUACUCAAAUAUUUAACGUUA ACGUUAAAUAUUUGAGUACAG 
 
siMDM4-317 317-339 GGUCAUGCACUAUUUAGGUCA ACCUAAAUAGUGCAUGACCUC 
 
siMDM4-347 347-369 GGUGAAGCAACUUUAUGAUCA AUCAUAAAGUUGCUUCACCAU 
 
siMDM4-452 452-474 CCCUCUCUAUGAUAUGCUAAG UAGCAUAUCAUAGAGAGGGCU 
 
siMDM4-525 525-547 GCUCUCGCACAGGAUCACAGU UGUGAUCCUGUGCGAGAGCGA 
 
siMDM4-582 582-604 GCAGAGGAAAGUUCCACUUCC AAGUGGAACUUUCCUCUGCAC 
 
siMDM4-788 788-810 CAACUAUACACCUAGAAGUAA ACUUCUAGGUGUAUAGUUGCU 
 
siMDM4-861 861-883 GAUACUACAGAUGACUUGUGG ACAAGUCAUCUGUAGUAUCUG 
 
siMDM4-1036 1036-1058 GUGAUGAUACCGAUGUAGAGG UCUACAUCGGUAUCAUCACUU 
 
siMDM4-1492 1492-1514 GACCACGAGACGGGAACAUUA AUGUUCCCGUCUCGUGGUCUU 
 
siMDM4-2263 2263-2285 GAGACUAUAGACUAGCAUAAC UAUGCUAGUCUAUAGUCUCAG 
 
siControl  
 
GUACCGCACGUCAUUCGUAUC UACGAAUGACGUGCGGUACGU 
 
siControl-R   CCGUACUAGCCAUUAUGCGUC CGCAUAAUGGCUAGUACGGGU   
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